| ||||||||||||||||||||||
| ||||||||||||||||||||||
| ||||||||||||||||||||||
1 | AN ACT concerning criminal law. | |||||||||||||||||||||
2 | Be it enacted by the People of the State of Illinois, | |||||||||||||||||||||
3 | represented in the General Assembly: | |||||||||||||||||||||
4 | Section 5. The Illinois Controlled Substances Act is | |||||||||||||||||||||
5 | amended by changing Sections 316.1 and 318 as follows: | |||||||||||||||||||||
6 | (720 ILCS 570/316.1) | |||||||||||||||||||||
7 | (This Section may contain text from a Public Act with a | |||||||||||||||||||||
8 | delayed effective date ) | |||||||||||||||||||||
9 | Sec. 316.1. Access to the integration of pharmacy records | |||||||||||||||||||||
10 | with the Prescription Monitoring Program. | |||||||||||||||||||||
11 | (a) Subject to the requirements and limitations set out in | |||||||||||||||||||||
12 | this Section and in administrative rule , the Department shall | |||||||||||||||||||||
13 | not require, either expressly or effectively, Electronic | |||||||||||||||||||||
14 | Health Records Systems, pharmacies, or other providers to | |||||||||||||||||||||
15 | utilize a particular entity or system for access to the | |||||||||||||||||||||
16 | integration of pharmacy records with the Prescription | |||||||||||||||||||||
17 | Monitoring Program. | |||||||||||||||||||||
18 | (1) Any entity or system for integration (transmitting | |||||||||||||||||||||
19 | the data maintained by the Prescription Monitoring | |||||||||||||||||||||
20 | Program) into an Electronic Health Records System, | |||||||||||||||||||||
21 | Certified Health IT Module, Pharmacy Dispensing System, or | |||||||||||||||||||||
22 | Pharmacy Management System that meets either the | |||||||||||||||||||||
23 | requirements of at least one certification criterion |
| |||||||
| |||||||
1 | adopted under the Office of National Coordinator for | ||||||
2 | Health Information Technology (ONC) or HITRUST | ||||||
3 | certification shall be deemed qualified by the Department | ||||||
4 | to integrate pharmacy records with the Prescription | ||||||
5 | Monitoring Program, subject to must meet applicable | ||||||
6 | requirements outlined in administrative rule, including, | ||||||
7 | but not limited to, the following: | ||||||
8 | (A) enter into a data sharing agreement with the | ||||||
9 | Department of Human Services, Prescription Monitoring | ||||||
10 | Program; | ||||||
11 | (B) all security requirements noted within this | ||||||
12 | Section , administrative rule, and all other applicable | ||||||
13 | State and federal security and privacy requirements; | ||||||
14 | (C) the Prescription Monitoring Program shall have | ||||||
15 | administrative control over the approval of each site | ||||||
16 | and individual integration point and the Prescription | ||||||
17 | Monitoring Program shall have the ability to disable | ||||||
18 | individual integration points, at no additional cost | ||||||
19 | to the State; | ||||||
20 | (D) interstate data sharing shall be completed | ||||||
21 | with written authorization from the Prescription | ||||||
22 | Monitoring Program; | ||||||
23 | (E) data available from the Prescription | ||||||
24 | Monitoring Program shall not be stored, cached, or | ||||||
25 | sold and the State may inspect and review an entity or | ||||||
26 | system for integration to assure and confirm the same, |
| |||||||
| |||||||
1 | subject to a reasonable non-disclosure agreement, as | ||||||
2 | permitted by State law, to protect the entity's or | ||||||
3 | system's trade secrets or other proprietary | ||||||
4 | information; | ||||||
5 | (F) analysis of data shall only be allowed with | ||||||
6 | express written permission from the Prescription | ||||||
7 | Monitoring Program; and | ||||||
8 | (G) access to audit data, shall be available in | ||||||
9 | hourly to real-time increments at no cost to the | ||||||
10 | State. | ||||||
11 | (2) Electronic Health Record Systems, Certified Health | ||||||
12 | IT Modules, Pharmacy Management Systems, and Pharmacy | ||||||
13 | Dispensing Systems integrated with the Prescription | ||||||
14 | Monitoring Program must meet applicable requirements | ||||||
15 | outlined in rule, including, but not limited to, the | ||||||
16 | following: | ||||||
17 | (A) provide their customers (healthcare entity, | ||||||
18 | pharmacy, provider, prescriber, dispenser, etc.) the | ||||||
19 | choice of approved integration vendor, meeting the | ||||||
20 | requirements of this Section and administrative rule, | ||||||
21 | or direct connect to the Illinois Prescription | ||||||
22 | Monitoring Program; | ||||||
23 | (B) provide their customers with access to the | ||||||
24 | data provided by the customer's chosen integration | ||||||
25 | vendor as allowed under State and federal statute; and | ||||||
26 | (C) follow all State and federal security and |
| |||||||
| |||||||
1 | privacy standards. | ||||||
2 | (3) Customers required to integrate under State or | ||||||
3 | federal law must meet the requirements outlined in | ||||||
4 | administrative rule, including, but not limited to, the | ||||||
5 | following: | ||||||
6 | (A) the customer retains the choice of which | ||||||
7 | integration vendor or direct connect is utilized to | ||||||
8 | connect to the Illinois Prescription Monitoring | ||||||
9 | Program; and | ||||||
10 | (B) customers seeking to contract with a new | ||||||
11 | integration vendor, shall enter into a memorandum of | ||||||
12 | understanding with the Prescription Monitoring | ||||||
13 | Program. | ||||||
14 | (b) The Illinois Prescription Monitoring Program may | ||||||
15 | exercise the power, by rule, to require Memoranda of | ||||||
16 | Understanding with all customers. The general contents of the | ||||||
17 | memorandum of understanding shall be set out in rule and shall | ||||||
18 | include, but not be limited to: | ||||||
19 | (1) the acknowledgment and choice of the customer of | ||||||
20 | the method of integration with the Prescription Monitoring | ||||||
21 | Program and | ||||||
22 | (2) the data use and other requirements on the | ||||||
23 | customer in accessing and using the Prescription | ||||||
24 | Monitoring Program. | ||||||
25 | A fee cannot be levied as part of a memorandum of | ||||||
26 | understanding required by the Department under this Section. |
| |||||||
| |||||||
1 | (c) Non-compliance by the Integration Vendor, Electronic | ||||||
2 | Health Record System, Certified Health IT Module, Pharmacy | ||||||
3 | Management System or Pharmacy Dispensing System, customer, or | ||||||
4 | any parties required to comply with this Section may result in | ||||||
5 | the party being prohibited from serving as entity or system | ||||||
6 | for integration with the Prescription Monitoring Program, | ||||||
7 | termination of contracts, agreements, or other business | ||||||
8 | relationships. The Department shall institute appropriate cure | ||||||
9 | notices, as necessary to remedy non-compliance. | ||||||
10 | (Source: P.A. 103-477, eff. 7-1-24.) | ||||||
11 | (720 ILCS 570/318) | ||||||
12 | Sec. 318. Confidentiality of information. | ||||||
13 | (a) Information received by the central repository under | ||||||
14 | Section 316 and former Section 321 is confidential. | ||||||
15 | (a-1) To ensure the federal Health Insurance Portability | ||||||
16 | and Accountability Act and confidentiality of substance use | ||||||
17 | disorder patient records rules that mandate the privacy of an | ||||||
18 | individual's prescription data reported to the Prescription | ||||||
19 | Monitoring Program received from a retail dispenser under this | ||||||
20 | Act, and in order to execute the duties and responsibilities | ||||||
21 | under Section 316 of this Act and rules for disclosure under | ||||||
22 | this Section, the Clinical Director of the Prescription | ||||||
23 | Monitoring Program or his or her designee shall maintain | ||||||
24 | direct access to all Prescription Monitoring Program data. Any | ||||||
25 | request for Prescription Monitoring Program data from any |
| |||||||
| |||||||
1 | other department or agency must be approved in writing by the | ||||||
2 | Clinical Director of the Prescription Monitoring Program or | ||||||
3 | his or her designee unless otherwise permitted by law. | ||||||
4 | Prescription Monitoring Program data shall only be disclosed | ||||||
5 | as permitted by law. | ||||||
6 | (a-2) As an active step to address the current opioid | ||||||
7 | crisis in this State and to prevent and reduce addiction | ||||||
8 | resulting from a sports injury or an accident, the | ||||||
9 | Prescription Monitoring Program and the Department of Public | ||||||
10 | Health shall coordinate a continuous review of the | ||||||
11 | Prescription Monitoring Program and the Department of Public | ||||||
12 | Health data to determine if a patient may be at risk of opioid | ||||||
13 | addiction. Each patient discharged from any medical facility | ||||||
14 | with an International Classification of Disease, 10th edition | ||||||
15 | code related to a sport or accident injury shall be subject to | ||||||
16 | the data review. If the discharged patient is dispensed a | ||||||
17 | controlled substance, the Prescription Monitoring Program | ||||||
18 | shall alert the patient's prescriber as to the addiction risk | ||||||
19 | and urge each to follow the Centers for Disease Control and | ||||||
20 | Prevention guidelines or his or her respective profession's | ||||||
21 | treatment guidelines related to the patient's injury. This | ||||||
22 | subsection (a-2), other than this sentence, is inoperative on | ||||||
23 | or after January 1, 2024. | ||||||
24 | (b) The Department must carry out a program to protect the | ||||||
25 | confidentiality of the information described in subsection | ||||||
26 | (a). The Department may disclose the information to another |
| |||||||
| |||||||
1 | person only under subsection (c), (d), or (f) and may charge a | ||||||
2 | fee not to exceed the actual cost of furnishing the | ||||||
3 | information. | ||||||
4 | (c) The Department may disclose confidential information | ||||||
5 | described in subsection (a) to any person who is engaged in | ||||||
6 | receiving, processing, or storing the information. | ||||||
7 | (d) The Department may release confidential information | ||||||
8 | described in subsection (a) to the following persons: | ||||||
9 | (1) A governing body that licenses practitioners and | ||||||
10 | is engaged in an investigation, an adjudication, or a | ||||||
11 | prosecution of a violation under any State or federal law | ||||||
12 | that involves a controlled substance. | ||||||
13 | (2) An investigator for the Consumer Protection | ||||||
14 | Division of the office of the Attorney General, a | ||||||
15 | prosecuting attorney, the Attorney General, a deputy | ||||||
16 | Attorney General, or an investigator from the office of | ||||||
17 | the Attorney General, who is engaged in any of the | ||||||
18 | following activities involving controlled substances: | ||||||
19 | (A) an investigation; | ||||||
20 | (B) an adjudication; or | ||||||
21 | (C) a prosecution of a violation under any State | ||||||
22 | or federal law that involves a controlled substance. | ||||||
23 | (3) A law enforcement officer who is: | ||||||
24 | (A) authorized by the Illinois State Police or the | ||||||
25 | office of a county sheriff or State's Attorney or | ||||||
26 | municipal police department of Illinois to receive |
| |||||||
| |||||||
1 | information of the type requested for the purpose of | ||||||
2 | investigations involving controlled substances; or | ||||||
3 | (B) approved by the Department to receive | ||||||
4 | information of the type requested for the purpose of | ||||||
5 | investigations involving controlled substances; and | ||||||
6 | (C) engaged in the investigation or prosecution of | ||||||
7 | a violation under any State or federal law that | ||||||
8 | involves a controlled substance. | ||||||
9 | (4) Select representatives of the Department of | ||||||
10 | Children and Family Services through the indirect online | ||||||
11 | request process. Access shall be established by an | ||||||
12 | intergovernmental agreement between the Department of | ||||||
13 | Children and Family Services and the Department of Human | ||||||
14 | Services. | ||||||
15 | (e) Before the Department releases confidential | ||||||
16 | information under subsection (d), the applicant must | ||||||
17 | demonstrate in writing to the Department that: | ||||||
18 | (1) the applicant has reason to believe that a | ||||||
19 | violation under any State or federal law that involves a | ||||||
20 | controlled substance has occurred; and | ||||||
21 | (2) the requested information is reasonably related to | ||||||
22 | the investigation, adjudication, or prosecution of the | ||||||
23 | violation described in subdivision (1). | ||||||
24 | (f) The Department may receive and release prescription | ||||||
25 | record information under Section 316 and former Section 321 | ||||||
26 | to: |
| |||||||
| |||||||
1 | (1) a governing body that licenses practitioners; | ||||||
2 | (2) an investigator for the Consumer Protection | ||||||
3 | Division of the office of the Attorney General, a | ||||||
4 | prosecuting attorney, the Attorney General, a deputy | ||||||
5 | Attorney General, or an investigator from the office of | ||||||
6 | the Attorney General; | ||||||
7 | (3) any Illinois law enforcement officer who is: | ||||||
8 | (A) authorized to receive the type of information | ||||||
9 | released; and | ||||||
10 | (B) approved by the Department to receive the type | ||||||
11 | of information released; or | ||||||
12 | (4) prescription monitoring entities in other states | ||||||
13 | per the provisions outlined in subsection (g) and (h) | ||||||
14 | below; | ||||||
15 | confidential prescription record information collected under | ||||||
16 | Sections 316 and 321 (now repealed) that identifies vendors or | ||||||
17 | practitioners, or both, who are prescribing or dispensing | ||||||
18 | large quantities of Schedule II, III, IV, or V controlled | ||||||
19 | substances outside the scope of their practice, pharmacy, or | ||||||
20 | business, as determined by the Advisory Committee created by | ||||||
21 | Section 320. | ||||||
22 | (f-5) In accordance with a confidentiality agreement | ||||||
23 | entered into with the Department, a medical director, or a | ||||||
24 | public health administrator and their delegated analysts, of a | ||||||
25 | county or municipal health department or the Department of | ||||||
26 | Public Health shall have access to data from the system for any |
| |||||||
| |||||||
1 | of the following purposes: | ||||||
2 | (1) developing education programs or public health | ||||||
3 | interventions relating to prescribing trends and | ||||||
4 | controlled substance use; or | ||||||
5 | (2) conducting analyses and publish reports on | ||||||
6 | prescribing trends in their respective jurisdictions. | ||||||
7 | At a minimum, the confidentiality agreement entered into | ||||||
8 | with the Department shall: | ||||||
9 | (i) prohibit analysis and reports produced under | ||||||
10 | subparagraph (2) from including information that | ||||||
11 | identifies, by name, license, or address, any | ||||||
12 | practitioner, dispenser, ultimate user, or other person | ||||||
13 | administering a controlled substance; and | ||||||
14 | (ii) specify the appropriate technical and physical | ||||||
15 | safeguards that the county or municipal health department | ||||||
16 | must implement to ensure the privacy and security of data | ||||||
17 | obtained from the system. The data from the system shall | ||||||
18 | not be admissible as evidence, nor discoverable in any | ||||||
19 | action of any kind in any court or before any tribunal, | ||||||
20 | board, agency, or person. The disclosure of any such | ||||||
21 | information or data, whether proper or improper, shall not | ||||||
22 | waive or have any effect upon its confidentiality, | ||||||
23 | non-discoverability, or non-admissibility. | ||||||
24 | (g) The information described in subsection (f) may not be | ||||||
25 | released until it has been reviewed by an employee of the | ||||||
26 | Department who is licensed as a prescriber or a dispenser and |
| |||||||
| |||||||
1 | until that employee has certified that further investigation | ||||||
2 | is warranted. However, failure to comply with this subsection | ||||||
3 | (g) does not invalidate the use of any evidence that is | ||||||
4 | otherwise admissible in a proceeding described in subsection | ||||||
5 | (h). | ||||||
6 | (h) An investigator or a law enforcement officer receiving | ||||||
7 | confidential information under subsection (c), (d), or (f) may | ||||||
8 | disclose the information to a law enforcement officer or an | ||||||
9 | attorney for the office of the Attorney General for use as | ||||||
10 | evidence in the following: | ||||||
11 | (1) A proceeding under any State or federal law that | ||||||
12 | involves a controlled substance. | ||||||
13 | (2) A criminal proceeding or a proceeding in juvenile | ||||||
14 | court that involves a controlled substance. | ||||||
15 | (i) The Department may compile statistical reports from | ||||||
16 | the information described in subsection (a). The reports must | ||||||
17 | not include information that identifies, by name, license or | ||||||
18 | address, any practitioner, dispenser, ultimate user, or other | ||||||
19 | person administering a controlled substance. | ||||||
20 | (j) Based upon federal, initial and maintenance funding, a | ||||||
21 | prescriber and dispenser inquiry system shall be developed to | ||||||
22 | assist the health care community in its goal of effective | ||||||
23 | clinical practice and to prevent patients from diverting or | ||||||
24 | abusing medications. | ||||||
25 | (1) An inquirer shall have read-only access to a | ||||||
26 | stand-alone database which shall contain records for the |
| |||||||
| |||||||
1 | previous 12 months. | ||||||
2 | (2) Dispensers may, upon positive and secure | ||||||
3 | identification, make an inquiry on a patient or customer | ||||||
4 | solely for a medical purpose as delineated within the | ||||||
5 | federal HIPAA law. | ||||||
6 | (3) The Department shall provide a one-to-one secure | ||||||
7 | link and encrypted software necessary to establish the | ||||||
8 | link between an inquirer and the Department. Technical | ||||||
9 | assistance shall also be provided. "One-to-one secure | ||||||
10 | link" only means connecting a provider and the Illinois | ||||||
11 | Prescription Monitoring Program through an electronic | ||||||
12 | health record or a pharmacy management system by issuing | ||||||
13 | unique credentials for each connecting system that can be | ||||||
14 | individually approved or denied by the Illinois | ||||||
15 | Prescription Monitoring Program. "One-to-one secure link" | ||||||
16 | refers only to the access controls and approval of | ||||||
17 | credentials, not the routing path of the transaction. | ||||||
18 | "One-to-one secure link" or "one-to-one connection" does | ||||||
19 | not mean that the integrating service will provide a | ||||||
20 | direct connection between the Electronic health Records | ||||||
21 | System or pharmacy management system and the Illinois | ||||||
22 | Prescription Monitoring Program. | ||||||
23 | (4) Written inquiries are acceptable but must include | ||||||
24 | the fee and the requester's Drug Enforcement | ||||||
25 | Administration license number and submitted upon the | ||||||
26 | requester's business stationery. |
| |||||||
| |||||||
1 | (5) As directed by the Prescription Monitoring Program | ||||||
2 | Advisory Committee and the Clinical Director for the | ||||||
3 | Prescription Monitoring Program, aggregate data that does | ||||||
4 | not indicate any prescriber, practitioner, dispenser, or | ||||||
5 | patient may be used for clinical studies. | ||||||
6 | (6) Tracking analysis shall be established and used | ||||||
7 | per administrative rule. | ||||||
8 | (7) Nothing in this Act or Illinois law shall be | ||||||
9 | construed to require a prescriber or dispenser to make use | ||||||
10 | of this inquiry system. | ||||||
11 | (8) If there is an adverse outcome because of a | ||||||
12 | prescriber or dispenser making an inquiry, which is | ||||||
13 | initiated in good faith, the prescriber or dispenser shall | ||||||
14 | be held harmless from any civil liability. | ||||||
15 | (k) The Department shall establish, by rule, the process | ||||||
16 | by which to evaluate possible erroneous association of | ||||||
17 | prescriptions to any licensed prescriber or end user of the | ||||||
18 | Illinois Prescription Information Library (PIL). | ||||||
19 | (l) The Prescription Monitoring Program Advisory Committee | ||||||
20 | is authorized to evaluate the need for and method of | ||||||
21 | establishing a patient specific identifier. | ||||||
22 | (m) Patients who identify prescriptions attributed to them | ||||||
23 | that were not obtained by them shall be given access to their | ||||||
24 | personal prescription history pursuant to the validation | ||||||
25 | process as set forth by administrative rule. | ||||||
26 | (n) The Prescription Monitoring Program is authorized to |
| |||||||
| |||||||
1 | develop operational push reports to entities with compatible | ||||||
2 | electronic medical records. The process shall be covered | ||||||
3 | within administrative rule established by the Department. | ||||||
4 | (o) Hospital emergency departments and freestanding | ||||||
5 | healthcare facilities providing healthcare to walk-in patients | ||||||
6 | may obtain, for the purpose of improving patient care, a | ||||||
7 | unique identifier for each shift to utilize the PIL system. | ||||||
8 | (p) The Prescription Monitoring Program shall | ||||||
9 | automatically create a log-in to the inquiry system when a | ||||||
10 | prescriber or dispenser obtains or renews his or her | ||||||
11 | controlled substance license. The Department of Financial and | ||||||
12 | Professional Regulation must provide the Prescription | ||||||
13 | Monitoring Program with electronic access to the license | ||||||
14 | information of a prescriber or dispenser to facilitate the | ||||||
15 | creation of this profile. The Prescription Monitoring Program | ||||||
16 | shall send the prescriber or dispenser information regarding | ||||||
17 | the inquiry system, including instructions on how to log into | ||||||
18 | the system, instructions on how to use the system to promote | ||||||
19 | effective clinical practice, and opportunities for continuing | ||||||
20 | education for the prescribing of controlled substances. The | ||||||
21 | Prescription Monitoring Program shall also send to all | ||||||
22 | enrolled prescribers, dispensers, and designees information | ||||||
23 | regarding the unsolicited reports produced pursuant to Section | ||||||
24 | 314.5 of this Act. | ||||||
25 | (q) A prescriber or dispenser may authorize a designee to | ||||||
26 | consult the inquiry system established by the Department under |
| |||||||
| |||||||
1 | this subsection on his or her behalf, provided that all the | ||||||
2 | following conditions are met: | ||||||
3 | (1) the designee so authorized is employed by the same | ||||||
4 | hospital or health care system; is employed by the same | ||||||
5 | professional practice; or is under contract with such | ||||||
6 | practice, hospital, or health care system; | ||||||
7 | (2) the prescriber or dispenser takes reasonable steps | ||||||
8 | to ensure that such designee is sufficiently competent in | ||||||
9 | the use of the inquiry system; | ||||||
10 | (3) the prescriber or dispenser remains responsible | ||||||
11 | for ensuring that access to the inquiry system by the | ||||||
12 | designee is limited to authorized purposes and occurs in a | ||||||
13 | manner that protects the confidentiality of the | ||||||
14 | information obtained from the inquiry system, and remains | ||||||
15 | responsible for any breach of confidentiality; and | ||||||
16 | (4) the ultimate decision as to whether or not to | ||||||
17 | prescribe or dispense a controlled substance remains with | ||||||
18 | the prescriber or dispenser. | ||||||
19 | The Prescription Monitoring Program shall send to | ||||||
20 | registered designees information regarding the inquiry system, | ||||||
21 | including instructions on how to log onto the system. | ||||||
22 | (r) The Prescription Monitoring Program shall maintain an | ||||||
23 | Internet website in conjunction with its prescriber and | ||||||
24 | dispenser inquiry system. This website shall include, at a | ||||||
25 | minimum, the following information: | ||||||
26 | (1) current clinical guidelines developed by health |
| |||||||
| |||||||
1 | care professional organizations on the prescribing of | ||||||
2 | opioids or other controlled substances as determined by | ||||||
3 | the Advisory Committee; | ||||||
4 | (2) accredited continuing education programs related | ||||||
5 | to prescribing of controlled substances; | ||||||
6 | (3) programs or information developed by health care | ||||||
7 | professionals that may be used to assess patients or help | ||||||
8 | ensure compliance with prescriptions; | ||||||
9 | (4) updates from the Food and Drug Administration, the | ||||||
10 | Centers for Disease Control and Prevention, and other | ||||||
11 | public and private organizations which are relevant to | ||||||
12 | prescribing; | ||||||
13 | (5) relevant medical studies related to prescribing; | ||||||
14 | (6) other information regarding the prescription of | ||||||
15 | controlled substances; and | ||||||
16 | (7) information regarding prescription drug disposal | ||||||
17 | events, including take-back programs or other disposal | ||||||
18 | options or events. | ||||||
19 | The content of the Internet website shall be periodically | ||||||
20 | reviewed by the Prescription Monitoring Program Advisory | ||||||
21 | Committee as set forth in Section 320 and updated in | ||||||
22 | accordance with the recommendation of the advisory committee. | ||||||
23 | (s) The Prescription Monitoring Program shall regularly | ||||||
24 | send electronic updates to the registered users of the | ||||||
25 | Program. The Prescription Monitoring Program Advisory | ||||||
26 | Committee shall review any communications sent to registered |
| |||||||
| |||||||
1 | users and also make recommendations for communications as set | ||||||
2 | forth in Section 320. These updates shall include the | ||||||
3 | following information: | ||||||
4 | (1) opportunities for accredited continuing education | ||||||
5 | programs related to prescribing of controlled substances; | ||||||
6 | (2) current clinical guidelines developed by health | ||||||
7 | care professional organizations on the prescribing of | ||||||
8 | opioids or other drugs as determined by the Advisory | ||||||
9 | Committee; | ||||||
10 | (3) programs or information developed by health care | ||||||
11 | professionals that may be used to assess patients or help | ||||||
12 | ensure compliance with prescriptions; | ||||||
13 | (4) updates from the Food and Drug Administration, the | ||||||
14 | Centers for Disease Control and Prevention, and other | ||||||
15 | public and private organizations which are relevant to | ||||||
16 | prescribing; | ||||||
17 | (5) relevant medical studies related to prescribing; | ||||||
18 | (6) other information regarding prescribing of | ||||||
19 | controlled substances; | ||||||
20 | (7) information regarding prescription drug disposal | ||||||
21 | events, including take-back programs or other disposal | ||||||
22 | options or events; and | ||||||
23 | (8) reminders that the Prescription Monitoring Program | ||||||
24 | is a useful clinical tool. | ||||||
25 | (t) Notwithstanding any other provision of this Act, | ||||||
26 | neither the Prescription Monitoring Program nor any other |
| |||||||
| |||||||
1 | person shall disclose any information in violation of the | ||||||
2 | restrictions and requirements of paragraph (3.5) of subsection | ||||||
3 | (a) of Section 316 as implemented under Public Act 102-527. | ||||||
4 | (Source: P.A. 102-751, eff. 1-1-23 .) |